These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 1959701

  • 21. Aldose reductase and retinal capillary basement membrane thickening.
    Robison WG, Nagata M, Kinoshita JH.
    Exp Eye Res; 1988 Mar; 46(3):343-8. PubMed ID: 3127228
    [Abstract] [Full Text] [Related]

  • 22. Pathogenetic heterogeneity in retinal capillary basement membrane thickening in the diabetic BB-rat.
    Chakrabarti S, Sima AA.
    Diabetologia; 1987 Dec; 30(12):966-8. PubMed ID: 3125081
    [Abstract] [Full Text] [Related]

  • 23. Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors.
    Robison WG.
    Adv Exp Med Biol; 1988 Dec; 246():365-72. PubMed ID: 3150650
    [Abstract] [Full Text] [Related]

  • 24. Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells.
    Srivastava S, Ramana KV, Tammali R, Srivastava SK, Bhatnagar A.
    Diabetes; 2006 Apr; 55(4):901-10. PubMed ID: 16567509
    [Abstract] [Full Text] [Related]

  • 25. Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
    Isogai S, Inokuchi T, Ohe K.
    Diabetes Res Clin Pract; 1995 Nov; 30(2):111-6. PubMed ID: 8833631
    [Abstract] [Full Text] [Related]

  • 26. Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.
    Forster HG, ter Wee PM, Hohman TC, Epstein M.
    Diabetologia; 1996 Aug; 39(8):907-14. PubMed ID: 8858212
    [Abstract] [Full Text] [Related]

  • 27. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
    Simard-Duquesne N, Greselin E, Dubuc J, Dvornik D.
    Metabolism; 1985 Oct; 34(10):885-92. PubMed ID: 3930915
    [Abstract] [Full Text] [Related]

  • 28. Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial.
    van Gerven JM, Boot JP, Lemkes HH, van Best JA.
    Doc Ophthalmol; 1994 Oct; 87(4):355-65. PubMed ID: 7851219
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients.
    Ihm SH, Yoo HJ, Park SW, Park CJ.
    Metabolism; 1997 Jun; 46(6):634-8. PubMed ID: 9186297
    [Abstract] [Full Text] [Related]

  • 33. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
    Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G.
    Diabetologia; 1995 Apr; 38(4):387-94. PubMed ID: 7796978
    [Abstract] [Full Text] [Related]

  • 34. Aldose reductase inhibition, Doppler flux and conduction in diabetic rat nerve.
    Calcutt NA, Mizisin AP, Kalichman MW.
    Eur J Pharmacol; 1994 Jan 04; 251(1):27-33. PubMed ID: 8137868
    [Abstract] [Full Text] [Related]

  • 35. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B.
    J Diabetes Complications; 1993 Jan 04; 7(3):170-8. PubMed ID: 8343611
    [Abstract] [Full Text] [Related]

  • 36. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
    Das A, Frank RN, Zhang NL, Samadani E.
    Exp Eye Res; 1990 Mar 04; 50(3):269-80. PubMed ID: 2108050
    [Abstract] [Full Text] [Related]

  • 37. Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats.
    Robison WG, Jacot JL, Glover JP, Basso MD, Hohman TC.
    Invest Ophthalmol Vis Sci; 1998 Sep 04; 39(10):1933-41. PubMed ID: 9727416
    [Abstract] [Full Text] [Related]

  • 38. Polyol pathway activity in nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose withdrawal or tolrestat intervention therapy.
    Sredy J, Sawicki DR, Notvest RR.
    J Diabet Complications; 1991 Sep 04; 5(1):42-7. PubMed ID: 1830318
    [Abstract] [Full Text] [Related]

  • 39. Glomerular basement membrane thickening in streptozotocin diabetic rats despite treatment with an aldose reductase inhibitor.
    Osterby R, Gundersen HJ.
    J Diabet Complications; 1989 Sep 04; 3(3):149-53. PubMed ID: 2528558
    [Abstract] [Full Text] [Related]

  • 40. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition.
    Engerman RL, Kern TS, Garment MB.
    J Diabetes Complications; 1993 Sep 04; 7(4):241-5. PubMed ID: 8219367
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.